David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer.
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/7/2026 | $4.00 | Buy | H.C. Wainwright | |
| 1/13/2025 | $4.00 | Outperform | Oppenheimer | |
| 1/12/2023 | $30.00 → $3.00 | Buy → Hold | Canaccord Genuity | |
| 8/5/2022 | $2.00 | Buy → Hold | Jefferies | |
| 2/25/2022 | $17.00 → $14.00 | Outperform | Oppenheimer | |
| 2/25/2022 | $16.00 → $9.00 | Outperform | SVB Leerink | |
| 2/18/2022 | $20.00 | Overweight | Cantor Fitzgerald | |
| 11/30/2021 | $17.00 → $32.00 | Buy | HC Wainwright & Co. |
6-K - COMPUGEN LTD (0001119774) (Filer)
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
HOLON, Israel, Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced the appointment of Michele Holcomb, Ph.D., as a new independent director, effective February 11, 2026. "On behalf of Compugen's Board of Directors, I am delighted to welcome Michele to the Board," said Anat Cohen-Dayag, Ph.D., Executive Chair, Compugen. "Michele brings more than three decades of experience spanning the biotech, pharmaceuticals and healthcare services industries. Her unique blend of strategic insights, corporate development, innovation and firsthand operation
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while retaining management of clinical programOramed will receive 49.9% beneficial ownership interest in Lifeward, a revenue-generating medical robotics company, including warrantsMark Grant, Lifeward CEO, with 25+ years experience in the diabetes sector at Medtronic and Bristol Myers Squibb, to lead combined platformsIn addition, strategic investment by Oramed designed to bring Lifeward towards profitabilityLifeward's FDA-approved ReWalk® and AlterG® products generated $26 million in last four quartersNE
Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties. Oramed retains a $27 million note and a $12 million convertible note with Scilex, convert
H.C. Wainwright initiated coverage of Compugen with a rating of Buy and set a new price target of $4.00
Oppenheimer initiated coverage of Compugen with a rating of Outperform and set a new price target of $4.00
Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously
HOLON, Israel, Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced the appointment of Michele Holcomb, Ph.D., as a new independent director, effective February 11, 2026. "On behalf of Compugen's Board of Directors, I am delighted to welcome Michele to the Board," said Anat Cohen-Dayag, Ph.D., Executive Chair, Compugen. "Michele brings more than three decades of experience spanning the biotech, pharmaceuticals and healthcare services industries. Her unique blend of strategic insights, corporate development, innovation and firsthand operation
Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f
HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day. David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer. "I am excited to welcome David to Compugen and believe his experience and insights will make him a pivotal additio
SC 13G - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
SC 13D - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties. Oramed retains a $27 million note and a $12 million convertible note with Scilex, convert
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025. Nine-Month Period 2025 Financial Highlights: Net income (pre-tax) of $65.0 million, compared to a net loss of $6.1 million in the same period last yearCompleted
NEW YORK, Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company. The Rights are designed to assure that all stockholders of the Company receive fair and equal treatment in the event of a hostile takeover of the Company, to guard against tactics designed to gain cont